DZ2522A1 - Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement. - Google Patents

Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement.

Info

Publication number
DZ2522A1
DZ2522A1 DZ980132A DZ980132A DZ2522A1 DZ 2522 A1 DZ2522 A1 DZ 2522A1 DZ 980132 A DZ980132 A DZ 980132A DZ 980132 A DZ980132 A DZ 980132A DZ 2522 A1 DZ2522 A1 DZ 2522A1
Authority
DZ
Algeria
Prior art keywords
insulin
treatment
composition
secretagogue
sensitizer
Prior art date
Application number
DZ980132A
Other languages
English (en)
French (fr)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2522A1 publication Critical patent/DZ2522A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ980132A 1997-06-18 1998-06-17 Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement. DZ2522A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
DZ2522A1 true DZ2522A1 (fr) 2003-02-01

Family

ID=26311744

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980132A DZ2522A1 (fr) 1997-06-18 1998-06-17 Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement.

Country Status (33)

Country Link
EP (3) EP2266576A1 (de)
JP (1) JP2001523270A (de)
KR (3) KR20070011651A (de)
CN (1) CN1168451C (de)
AP (1) AP1600A (de)
AR (2) AR008025A1 (de)
AT (1) ATE353654T1 (de)
AU (1) AU8539298A (de)
BG (2) BG109397A (de)
BR (1) BR9810142A (de)
CA (1) CA2294385C (de)
CO (1) CO4940457A1 (de)
CZ (1) CZ299310B6 (de)
DE (1) DE69837089T2 (de)
DZ (1) DZ2522A1 (de)
EA (1) EA003025B1 (de)
ES (1) ES2283064T3 (de)
ID (1) ID24065A (de)
IL (1) IL133137A (de)
IN (1) IN189319B (de)
MA (1) MA24571A1 (de)
MY (1) MY125855A (de)
NO (3) NO326263B1 (de)
NZ (1) NZ501163A (de)
OA (1) OA11510A (de)
PE (1) PE108199A1 (de)
PL (2) PL198018B1 (de)
SK (1) SK286028B6 (de)
TR (1) TR199903096T2 (de)
TW (1) TW542717B (de)
UA (1) UA67743C2 (de)
UY (1) UY25048A1 (de)
WO (1) WO1998057649A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE60004658T2 (de) 1999-04-23 2004-06-24 Smithkline Beecham Plc, Brentford Thiazolidindionderivat und seine verwendung als antidiabetikum
US7166584B1 (en) 1999-11-01 2007-01-23 Wisconsin Alumni Research Foundation Cholesterol transport gene
ATE508738T1 (de) 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
MXPA06004639A (es) * 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
ZA200805147B (en) 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR930701436A (ko) 1990-07-03 1993-06-11 오노다 마사아이 비스헤테로환 화합물
FI930772A0 (fi) 1990-08-23 1993-02-22 Pfizer Hydroxiureaderivat som saenker glugosnivao i blodet
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
CA2106967C (en) 1991-04-11 2003-12-09 Takashi Sohda Thiazolidinedione derivatives, production and use thereof
TW222626B (de) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
CA2139442A1 (en) 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
HK1028200A1 (en) 2001-02-09
IN189319B (de) 2003-02-08
NO326263B1 (no) 2008-10-27
EP2266576A1 (de) 2010-12-29
CO4940457A1 (es) 2000-07-24
BG109397A (bg) 2006-05-31
CZ9904577A3 (en) 2001-05-16
CZ299310B6 (cs) 2008-06-18
IL133137A (en) 2004-02-08
KR20070011651A (ko) 2007-01-24
CN1260719A (zh) 2000-07-19
AP9901717A0 (en) 1999-12-31
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
EA200000039A1 (ru) 2000-08-28
BG64817B1 (bg) 2006-05-31
KR20010013840A (ko) 2001-02-26
AP1600A (en) 2006-04-28
BR9810142A (pt) 2000-08-08
NZ501163A (en) 2002-02-01
DE69837089T2 (de) 2007-06-21
CA2294385A1 (en) 1998-12-23
EA003025B1 (ru) 2002-12-26
EP0999845B1 (de) 2007-02-14
ES2283064T3 (es) 2007-10-16
CN1168451C (zh) 2004-09-29
ATE353654T1 (de) 2007-03-15
NO996264L (no) 2000-02-17
CA2294385C (en) 2007-06-05
NO996264D0 (no) 1999-12-17
PL198018B1 (pl) 2008-05-30
DE69837089D1 (de) 2007-03-29
AR012996A1 (es) 2000-11-22
ID24065A (id) 2000-07-06
SK286028B6 (sk) 2008-01-07
AU8539298A (en) 1999-01-04
JP2001523270A (ja) 2001-11-20
EP1671637A2 (de) 2006-06-21
OA11510A (en) 2004-02-03
PL337510A1 (en) 2000-08-28
EP1671637A3 (de) 2007-12-19
KR20080011356A (ko) 2008-02-01
TW542717B (en) 2003-07-21
UA67743C2 (uk) 2004-07-15
BG104058A (en) 2000-10-31
IL133137A0 (en) 2001-03-19
AR008025A1 (es) 1999-12-09
NO2009002I1 (no) 2009-03-02
UY25048A1 (es) 2000-09-29
TR199903096T2 (xx) 2000-08-21
EP0999845A1 (de) 2000-05-17
MY125855A (en) 2006-08-30
MA24571A1 (fr) 1998-12-31
SK179199A3 (en) 2000-11-07
PE108199A1 (es) 2000-01-14

Similar Documents

Publication Publication Date Title
FR2690263B3 (fr) Procédé et appareil de développement d&#39;une forme bidimensionnelle.
DZ2520A1 (fr) Composition pharmaceutique pour une méthode de traitement du diabète sucré.
EP0638805A3 (de) Analyt-nachweis Gerät und Verfahren.
EP0654943A3 (de) Verfahren und Schaltung zur Bildverbesserung.
EP0673155A3 (de) Untersystem und Verfahren zur Korrektur von Daten für die Bildverarbeitung.
EP0623890A3 (de) Verfahren und Gerät zur Bildverarbeitung.
EP1008980A4 (de) Dynamisches bildkorrekturverfahren und dynamische bildkorrekturschaltung für anzeigevorrichtung
DZ2522A1 (fr) Composition comprenant un sensibilisant à l&#39;insuline et secrétagogue d&#39;insuline pour une méthode de traitement.
FR2716989B1 (fr) Procédé de fonctionnement d&#39;une carte à puce.
DZ2521A1 (fr) Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l&#39;insuline pour une méthode de traitement.
AU123249S (en) Developing processor for image formation
EP0667704A3 (de) Bildverarbeitungsgerät.
FR2716075B1 (fr) Procédé pour renforcer l&#39;efficacité d&#39;un produit chimique agricole, renforçateur et composition de renforçateur utilisés dans ce procédé et composition chimique agricole comprenant ce renforçateur.
EP0992868A4 (de) Verfahren und vorrichtung zur berechnung einer erforderlichen werkstoffmenge
DZ2519A1 (fr) Compositions pharmaceutiques comprenant un sensibilisant à l&#39;insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte.
FR2643474B1 (fr) Dispositif pour enregistrer un historique d&#39;execution dans une unite de traitement de l&#39;information
EP0935386A4 (de) Bildprozessor und integrierte schaltung dafür
FR2720843B1 (fr) Toner pour développer des images de charges statiques, et procédé pour le préparer.
EP0989753A4 (de) Bildprozessor und verfahren zur bildverarbeitung
FR2766044B1 (fr) Procede de traitement d&#39;une sequence d&#39;images radiologiques d&#39;un objet
EP0602704A3 (de) Verfahren zur Codierung einer Veränderungsposition in einer Bildfolge.
DZ2563A1 (fr) Composition contenant un sensibilisant à l&#39;insuline un secrétagogue d&#39;insuline et un biguanide anti-hyperglycérnique inhibiteur d&#39;alpha-glucosidase.
FR2691814B1 (fr) Procédé et appareillage d&#39;impression d&#39;une image.
EP0711992A3 (de) Verfahren zur Bestimmung einer fluoreszierenden Substanz, sowie Verfahren zur Enzym-Aktivität-Bestimmung
EP0804202A4 (de) Östrogene und parathyroidhormon zur behandlung der osteoporose